Get started
Divi's Laboratories LimitedDivi's Laboratories LimitedDivi's Laboratories Limited

Divi's Laboratories Limited

No trades
OverviewFinancialsNewsDocumentsIdeasMindsTechnicalsForecastsSeasonalsOptionsETFs

Trade ideas

Divis Laboratories Ltd. (DIVISLAB)When you look at the Davis Lab chart, the most striking feature is that it has a large time cycle of 147 days. The normal Jupiter cycle of 12 (1+2=3)is root 144 (12X12) days. We found that 147 days is a very stable time cycle in Davis Lab.Of all the time cycle charts we have discussed or provided so far, Davis Lab has the longest time cycle, at 147 days. At least two-three cycles in this have been run sideways, yet we saw that it has gone up almost 150 times from the record date low in the last 7 cycles. We will discuss the celestial cycles in the future.We will also discuss the chart of the planet's cycle. For now, here is the chart from Davis Lab.
NSE:DIVISLAB
by askbiswanath2025
DIVISLAB - Bullish Momentum + RSI & MACD Breakout📈 Divis Laboratories Ltd | Bullish Momentum + RSI & MACD Breakout 🚀 🔹 Entry Zone: ₹6,100 – ₹6,120 🔹 Stop Loss: ₹5,739.80 (Risk ~₹380 pts) 🔹 Supports: 5,917.33 / 5,730.17 / 5,628.83 🔹 Resistances: 6,205.83 / 6,307.17 / 6,494.33 ________________________________________ 🔑 Key Highlights ✅ Strong Bullish Candle – powerful reversal from key support zone ✅ RSI Breakout – momentum confirmation after prolonged base ✅ MACD Crossover – positive trend shift visible ✅ Bullish SuperTrend + VWAP Alignment – institutional momentum confirmation ✅ BB Squeeze-Off → volatility expansion expected ________________________________________ 🎯 STWP Trade View 📊 Momentum suggests a short-term bullish rally is in play. A close above ₹6,200 may open further upside toward ₹6,307 – ₹6,494. ⚠️ Supports at ₹5,917 & ₹5,730 act as crucial protection zones. Volume spike confirms fresh long build-up — a classic “Buy Today, Sell Tomorrow” setup. ________________________________________ 💡 Learning Note This setup beautifully showcases how combining RSI Breakout + MACD Crossover + VWAP alignment strengthens a momentum-based reversal. When such signals converge near Fibonacci supports, they offer high-probability swing setups with strong follow-through potential. ________________________________________ ⚠️ Disclosure & Disclaimer – Please Read Carefully The information shared here is purely for learning and awareness purposes. It is not a buy or sell recommendation and should not be treated as investment advice. I am not a SEBI-registered investment adviser — all observations are based on personal chart study and publicly available data. Trading involves risk — markets can move unexpectedly, and losses can exceed invested amounts. Past setups or patterns do not guarantee future outcomes. If you’re a beginner, treat this content as a learning reference and start with paper trades. If you’re experienced, align setups with your own risk and position sizing strategy. Always consult a SEBI-registered advisor before executing any trades. By engaging with this content, you accept full responsibility for your actions. ________________________________________ 💬 Found this useful? 🔼 Give this post a Boost to help more traders learn structured setups 💬 Drop your thoughts or chart views below — let’s grow together 🔁 Share with fellow traders who love clean, data-backed analysis 👉 “If you liked this breakdown, follow for more disciplined, structured setups.” 🚀 Stay Calm. Stay Clean. Trade With Patience. Trade Smart | Learn Zones | Be Self-Reliant 📊
NSE:DIVISLABLong
by simpletradewithpatience
DIVISLAB 1 Month Time Frame 📊 Key Financial Metrics Current Share Price: ₹6,046.00 Market Capitalization: ₹1,60,780 Crore Price-to-Earnings (P/E) Ratio (TTM): 69.65 Earnings Per Share (EPS): ₹86.81 Book Value per Share: ₹564 Dividend Yield: 0.51% Return on Equity (ROE): 14.64% Debt-to-Equity Ratio: 0.00 (virtually debt-free) Beta (5Y Monthly): 0.17 (indicating low volatility) Face Value: ₹2.00 📈 Recent Stock Performance (1-Month Overview) Price Range: ₹5,692.50 (Oct 1) – ₹5,898.00 (Oct 6) Average Price: Approximately ₹5,957.03 1-Month Change: Approximately -3.05%
NSE:DIVISLABLong
by Knowledgehub
Divis Labs: Stellar FY25 Results Set Stage for Fresh BreakoutTechnical Analysis Divis Laboratories has demonstrated exceptional technical progression with a super bullish rally spanning an incredible 2 decades, establishing itself as one of India's premier pharma success stories. The stock's consistent uptrend reflects the company's strong fundamentals and market leadership in the API segment. From October 2024, the ₹6,250-6,300 zone emerged as formidable resistance, creating a critical supply area that tested multiple times. However, the game-changing catalyst arrived with the announcement of stellar FY25 results showcasing record revenue growth and impressive profitability metrics. The positive FY25 performance and strong YoY growth provided the momentum needed to break above the stubborn ₹6,250-6,300 supply zone, with the stock rallying impressively to ₹7,071 - marking a significant 13% surge from resistance levels. However, profit-booking and market volatility caused a correction back to ₹5,800 levels, and the stock is now trading at ₹6,200, finding itself once again at the critical supply zone. This same resistance area that was conquered earlier now acts as a key battleground for the next directional move. Entry Strategy: Enter on confirmed breakout above ₹6,300 with strong volume, or accumulate on dips if ₹6,200 holds as support with bullish candlestick patterns. Targets: Target 1: ₹6,600 Target 2: ₹6,800 Target 3: ₹7,000 Stop Losses: Critical Stop: ₹6,100 (below current support zone) If this zone doesn't sustain and shows rejection, no more expectations on this stock. FY25 Financial Highlights (vs FY24 & FY23) Total Income: ₹9,360 Cr (↑ +19.3% YoY from ₹7,845 Cr; ↑ +20.5% vs ₹7,767 Cr in FY23) Total Expenses: ₹6,387 Cr (↑ +13.3% YoY from ₹5,635 Cr; ↑ +18.3% vs ₹5,397 Cr in FY23) Operating Profit: ₹2,973 Cr (↑ +34.5% YoY from ₹2,210 Cr; ↑ +25.4% vs ₹2,370 Cr in FY23) Profit Before Tax: ₹2,916 Cr (↑ +34.8% YoY from ₹2,163 Cr; ↑ +23.1% vs ₹2,369 Cr in FY23) Profit After Tax: ₹2,191 Cr (↑ +36.9% YoY from ₹1,600 Cr; ↑ +20.1% vs ₹1,824 Cr in FY23) Diluted EPS: ₹82.53 (↑ +37.0% YoY from ₹60.27; ↑ +20.1% vs ₹68.71 in FY23) Fundamental Highlights Divis Laboratories delivered spectacular FY25 performance with PAT surging an exceptional 36.9% YoY to ₹2,191 crore, driven by robust demand for APIs and strong execution across all business segments. Revenue surged 19% to Rs 9,712 crore while net profit jumped 37% to Rs 2,191 crore, reflecting strong demand for APIs and robust growth momentum. The company demonstrated remarkable quarterly consistency with Q3FY25 net profit of Rs 589 crore, up 64.5% Y-o-Y, and EBITDA rising to Rs 743 crore with margins improving to 32.04% from 26.9%. Q2 FY25 achieved consolidated revenue of ₹2,444 crore, up 22.50% YoY, with PAT of ₹510 crore, up 46.55% YoY. Market cap stands at ₹1,63,282 crore with the company maintaining healthy dividend payout of 43.2%, demonstrating strong cash generation capabilities. Divi's Laboratories stands out as the sector's most preferred name, valued for its strong track record and broad domestic ownership with mid- to long-term growth visibility. The company has positioned itself strategically for future growth with aggressive capex of ~₹1000-2000 crore including greenfield Kakinada plant over next two years to capture ~US$20 billion opportunity of APIs going off-patent over FY23-25. Strong business mix with custom synthesis and generics contributing 53% and 47% respectively, while EBITDA margins expanded from 26.4% to 32%, showcasing superior operational efficiency and pricing power in premium API segments. New Unit-3 operations started with ₹30/share dividend declared, indicating continued capacity expansion and shareholder-friendly policies. The company's focus on complex APIs and custom synthesis provides sustainable competitive advantages and higher margin profiles. It is rare to find an Indian pharma company which makes systematic investments towards building customer trust, improving compliance and ramping up manufacturing efficiency, positioning Divis as a quality leader in the global API space. Operating margin expansion from previous years demonstrates excellent cost management and operational leverage benefits. Strong balance sheet fundamentals and consistent profitability growth support the technical breakout thesis for sustained momentum in the premium pharma segment. Conclusion Divis Laboratories' outstanding 36.9% YoY PAT growth and 19.3% revenue surge in FY25, coupled with consistent quarterly outperformance, creates compelling technical and fundamental convergence at the critical ₹6,200-6,300 zone. The company's market leadership position, aggressive expansion plans targeting $20 billion off-patent opportunity, and strong sectoral tailwinds provide robust backing for sustained growth. Critical breakout above ₹6,300 with volume confirmation could unlock significant upside toward the ₹7,000 target zone. The 2-decade wealth creation journey continues with fresh technical setup favoring further upside in this premium API play. Disclaimer: tinyurl.com
NSE:DIVISLAB
by Alice Blue
1
Divis Labs: Stellar FY25 Results Set Stage for Fresh Breakout🔍 Technical Analysis Divis Laboratories has demonstrated exceptional technical progression with a super bullish rally spanning an incredible 2 decades, establishing itself as one of India's premier pharma success stories. The stock's consistent uptrend reflects the company's strong fundamentals and market leadership in the API segment. From October 2024, the ₹6,250-6,300 zone emerged as formidable resistance, creating a critical supply area that tested multiple times. However, the game-changing catalyst arrived with the announcement of stellar FY25 results showcasing record revenue growth and impressive profitability metrics. The positive FY25 performance and strong YoY growth provided the momentum needed to break above the stubborn ₹6,250-6,300 supply zone, with the stock rallying impressively to ₹7,071 - marking a significant 13% surge from resistance levels. However, profit-booking and market volatility caused a correction back to ₹5,800 levels, and the stock is now trading at ₹6,200, finding itself once again at the critical supply zone. This same resistance area that was conquered earlier now acts as a key battleground for the next directional move. Entry Strategy: Enter on confirmed breakout above ₹6,300 with strong volume, or accumulate on dips if ₹6,200 holds as support with bullish candlestick patterns. 🎯 Targets: Target 1: ₹6,600 Target 2: ₹6,800 Target 3: ₹7,000 🚫 Stop Losses: Critical Stop: ₹6,100 (below current support zone) If this zone doesn't sustain and shows rejection, no more expectations on this stock. 💰 FY25 Financial Highlights (vs FY24 & FY23) Total Income: ₹9,360 Cr (↑ +19.3% YoY from ₹7,845 Cr; ↑ +20.5% vs ₹7,767 Cr in FY23) Total Expenses: ₹6,387 Cr (↑ +13.3% YoY from ₹5,635 Cr; ↑ +18.3% vs ₹5,397 Cr in FY23) Operating Profit: ₹2,973 Cr (↑ +34.5% YoY from ₹2,210 Cr; ↑ +25.4% vs ₹2,370 Cr in FY23) Profit Before Tax: ₹2,916 Cr (↑ +34.8% YoY from ₹2,163 Cr; ↑ +23.1% vs ₹2,369 Cr in FY23) Profit After Tax: ₹2,191 Cr (↑ +36.9% YoY from ₹1,600 Cr; ↑ +20.1% vs ₹1,824 Cr in FY23) Diluted EPS: ₹82.53 (↑ +37.0% YoY from ₹60.27; ↑ +20.1% vs ₹68.71 in FY23) 🧠 Fundamental Highlights Divis Laboratories delivered spectacular FY25 performance with PAT surging an exceptional 36.9% YoY to ₹2,191 crore, driven by robust demand for APIs and strong execution across all business segments. Revenue surged 19% to Rs 9,712 crore while net profit jumped 37% to Rs 2,191 crore, reflecting strong demand for APIs and robust growth momentum. The company demonstrated remarkable quarterly consistency with Q3FY25 net profit of Rs 589 crore, up 64.5% Y-o-Y, and EBITDA rising to Rs 743 crore with margins improving to 32.04% from 26.9%. Q2 FY25 achieved consolidated revenue of ₹2,444 crore, up 22.50% YoY, with PAT of ₹510 crore, up 46.55% YoY. Market cap stands at ₹1,63,282 crore with the company maintaining healthy dividend payout of 43.2%, demonstrating strong cash generation capabilities. Divi's Laboratories stands out as the sector's most preferred name, valued for its strong track record and broad domestic ownership with mid- to long-term growth visibility. The company has positioned itself strategically for future growth with aggressive capex of ~₹1000-2000 crore including greenfield Kakinada plant over next two years to capture ~US$20 billion opportunity of APIs going off-patent over FY23-25. Strong business mix with custom synthesis and generics contributing 53% and 47% respectively, while EBITDA margins expanded from 26.4% to 32%, showcasing superior operational efficiency and pricing power in premium API segments. New Unit-3 operations started with ₹30/share dividend declared, indicating continued capacity expansion and shareholder-friendly policies. The company's focus on complex APIs and custom synthesis provides sustainable competitive advantages and higher margin profiles. It is rare to find an Indian pharma company which makes systematic investments towards building customer trust, improving compliance and ramping up manufacturing efficiency, positioning Divis as a quality leader in the global API space. Operating margin expansion from previous years demonstrates excellent cost management and operational leverage benefits. Strong balance sheet fundamentals and consistent profitability growth support the technical breakout thesis for sustained momentum in the premium pharma segment. ✅ Conclusion Divis Laboratories' outstanding 36.9% YoY PAT growth and 19.3% revenue surge in FY25, coupled with consistent quarterly outperformance, creates compelling technical and fundamental convergence at the critical ₹6,200-6,300 zone. The company's market leadership position, aggressive expansion plans targeting $20 billion off-patent opportunity, and strong sectoral tailwinds provide robust backing for sustained growth. Critical breakout above ₹6,300 with volume confirmation could unlock significant upside toward the ₹7,000 target zone. The 2-decade wealth creation journey continues with fresh technical setup favoring further upside in this premium API play.
NSE:DIVISLABLong
by Rupesh_Chidharala
Divi’s Laboratories – Wave (C) Decline Targeting Lower ZonesWave Count Divi’s Laboratories topped at ₹7,071.50, completing a 5-wave impulse. From there, price declined in five clear waves into Wave (A) at ₹5,856.50. The subsequent bounce unfolded as an abc zigzag, peaking at ₹6,314.50 — aligning perfectly with the 0.382 Fibonacci retracement of the 7,071.50–5,856.50 fall. Wave (B) therefore looks complete, though the possibility of a triangle cannot be fully dismissed. The structure now favors a Wave (C) decline, unfolding in five waves toward lower zones. Momentum RSI stays weak, repeatedly failing to break above 50. This confirms lack of bullish strength and supports the bearish case. Targets Wave (C) is expected to stretch into the ₹5,563–₹5,100 zone, defined by the 0.618-1.00 extension and prior structural supports. Trade Plan Bias: Bearish until Wave (C) completes Target zone: ₹5,563–₹5,100 Stop-loss / invalidation: Close above ₹6,350.50 Disclaimer: This analysis is for educational purposes only and does not constitute investment advice. Please do your own research (DYOR) before making any trading decisions.
NSE:DIVISLABShort
by WaveXplorer
DIVISLAB - Falling Wedge pattern Breakout --> BullishEntry @6248 ✅ Overall View Current Price: ₹6248.50 RSI (Relative Strength Index): 47.62 → This indicates a neutral zone (neither overbought nor oversold). ✅ Support and Resistance Levels Supports: S1: ₹6010 S2: ₹6020.35 S3: ₹6162 Price is above all supports, which is positive. Resistances: R1: ₹6248.90 (current price is very close) R2: ₹6275.85 R3: ₹6282.50 The stock is near its immediate resistance, so watch for a breakout above ₹6249–₹6282. ✅ Fibonacci Levels Key levels derived from previous swing: 23.6%: ₹3754.59 38.2%: ₹4388.45 50%: ₹4900.75 61.8%: ₹5413.05 78.6%: ₹6142.42 (Price is above this level → bullish sign) ✅ Moving Averages Short-Term: EMA5 = ₹6141.71, SMA5 = ₹6102.50 → Price is above both → short-term trend is positive. EMA9 = ₹6136.91, SMA9 = ₹6096.78 → Also bullish short-term. Medium-Term: EMA20 = ₹6237.30, SMA20 = ₹6240.43 → Price is slightly above → neutral to bullish. Long-Term: EMA50 = ₹6383.40, SMA50 = ₹6532.76 → Price is below → long-term still weak. EMA200 = ₹6038.53, SMA200 = ₹6107.82 → Price is above → long-term trend is positive. ✅ Interpretation RSI near 47 → Neutral (not overbought or oversold). Price near immediate resistance (6248.90) → If breaks above ₹6282 with volume, bullish momentum possible. Above major Fibonacci (78.6%) and above 200-day EMA/SMA → Long-term bullish bias. Medium-term and short-term averages show slight strength but need a breakout above ₹6282 for strong uptrend.
NSE:DIVISLABLong
by Data2Dreams
Understanding Volume ImbalancesUnderstanding Volume Imbalances – The Market’s Unfinished Business A Volume Imbalance occurs when price moves very quickly upward or downward, leaving behind price zones where little or no trading has taken place – often called No Trade Zones. These imbalances can be spotted on the daily timeframe and are similar in nature to gap ups or gap downs. They typically happen due to strong news, institutional activity, or sudden shifts in sentiment. Market behavior shows that these gaps are often “filled” within 2–3 months, as price revisits these levels to balance out trading activity. For traders, these zones act as important reference points for future support, resistance, or potential trade targets. #VolumeImbalance #PriceAction #GapTrading #MarketStructure #TechnicalAnalysis #TrueDirections1
NSE:DIVISLAB
by VikasBajajICT
DIVISLAB: Flag & Pole Breakout Setup Targets New ATHsNSE: DIVISLAB | Pharmaceuticals | Large Cap | Updated: June 17, 2025 📊 Technical Structure Pole Formation: Rally from 4,955 → 6,862 (1,907 points) on high volume Flag Consolidation: Tight range between 6,490 (support) and 6,800 (resistance) Key Breakout Trigger: Daily close above 6,862 (ATH) Pattern Target: 8,769 (6,862 + 1,907 pole length) Critical Support: 6,300 (confirmed swing low) 🎯 Price Targets & Roadmap Immediate Target: 7,200 (2024 swing high) Strong Resistance Zone: 7,600-7,750 (analysts ceiling) Pattern Target: 8,769 (100% pole extension) Confirmation Required for 8,769: • Breakout volume >650K (20% above 20D avg) • Pharma sector PE >42 (currently 39.2) ⚡ Trade Strategy Scenario 1: ATH Breakout (Preferred) Entry: Daily close above 6,862 (6,880-6,900 zone) Targets: • 7,200 (book 30% profits) • 7,600 (book 50% profits) • 8,769 (full exit) Stop Loss: 6,700 Scenario 2: Flag Breakdown Entry: 6,300-6,160 (50-DMA confluence) Target: 6,800 flag retest → 7,200 Stop Loss: 6,050 Risk Management Essentials: Max 2% capital per trade ⚖️ Fundamental Drivers Strengths: • 15.4% ROE (vs sector 12.1%) • 17% EPS growth (FY26E) • FII holdings ↑2.1% YoY to 18.01% Risks: • High PE 79.2 (sector 39.2) • Overbought risk above 7,600 ⚠️ Critical Risks Valuation Risk: Profit-booking likely near 7,600 Sector Risk: Pharma index seasonality (+4.91% avg June) 📉 Real-Time Levels Current Price: ₹6,538 (-2.24% today) Support: 6,490 (flag base) → 6,300 (swing flip) Resistance: 6,800 (flag top) → 6,862 (ATH) Volume Alert: Breakout requires >650K shares ✅ Conclusion DIVISLAB offers a high-reward setup with defined risk parameters. The flag breakout above 6862 is the preferred play, backed by sector leadership and earnings growth. Always hedge with stops—overvaluation remains a concern. 📜 Disclaimer This analysis represents my personal market view and not investment advice. Trading carries significant risk of capital loss. Past performance doesn't guarantee future results. Always: Conduct your own due diligence Consider your risk tolerance Consult a SEBI-certified advisor Verify real-time data before acting Never risk more than you can afford to lose.
NSE:DIVISLABLong
by Alert_Trader
[DIVISLAB] - Potential pullback entry at the [RTS + DZ] STOCK TREND - BULLISH MULTI TF ANALYSIS ================= MONTHLY - Rounding Bottom + ATH breakout with good Volume WEEKLY - Box Consolidation near ATH DAILY - Box Consolidation + Resistance turned Support(RTS) level breakout TECHNICAL ANALYSIS =================== Stock Price is trading above RSI is above Support Level - Demand Zone - FUNDAMENTAL ANALYSIS ====================== Compounded Sales Growth - 19% Compounded Profit Growth - 37% Stock Price CAGR - 54% Return on Equity - 15% TRADE DESIGN ============== Potential pullback entry at the confluence of ENTRY - 6323 SL - 6000 TARGET - 7257 RRR - 1:2.89 Disclaimer: This chart study is for educational purpose only. Kindly trade at your own risk.
NSE:DIVISLABLong
by shubhambhopale
DIVISLAB -Inverted Head and Shoulders -DailyThanks for the clarification! Yes — the chart **does** resemble an **Inverted Head and Shoulders** pattern (a bullish reversal pattern), especially visible in the price structure before the breakout above ₹6,278. --- ### 🟢 **Inverted Head and Shoulders – Analysis (Divi's Lab)** #### **Pattern Structure:** * **Left Shoulder:** Formed in March. * **Head:** Deepest low around early April. * **Right Shoulder:** Higher low formed in late April to early May. * **Neckline:** Breakout above the ₹6,278 level confirms the pattern. #### **Breakout Confirmation:** * Breakout is strong, supported by **increasing volume**. * Target derived from neckline to head height = approx. ₹1,333. * **Target after breakout:** ₹6,278 + ₹1,333 = **₹7,611** (already marked on the chart). ---
NSE:DIVISLABLong
by DailyCharts03
DIVI S LABORATORIES LTDDIVI S LABORATORIES LTD DIVISLAB: Rounding Bottom Consolidation Breakout..!! DIVISLAB is showing good consolidation Breakout above the Rounding Bottom structure breakout.. target and sl are on the chart.... there is lot of scope in large cap stocks as the data shows.. All data is available in public domain.. CMP: 6580 TG: 7800 SL: 5840 Stock's selection based on 5 Point Analysis: 1: Idea : Breakout. 2: Support: Volume, Delivery. 3: Technical: 21/55/200-EMA, Super trend up, RS>0 RSI. 4: Fundamental: PE, PAT, Industry & peer PE and sector performance. 5: Timing: Entry Timing on Daily chart. Disclaimer: It is my personal view as a trader and for educational purpose only. Equity market involves risk. Please consult your financial adviser before taking any decision. Disclosure: might be Hold
NSE:DIVISLABLong
by TechnicalExpress
DIVISLAB - Cup Pattern Breakout with Bullish Flag Consolidation📊 DIVISLAB – Cup Pattern Breakout with Bullish Flag Consolidation 🕰️ Timeframe: 1W | 🔍 Pattern: Cup Formation + Bullish Flag | 🚀 Long-Term Breakout Potential 📈 Technical Breakdown: DIVISLAB has formed a massive Cup pattern on the weekly timeframe and is currently consolidating inside a Bullish Flag after hitting the neckline breakout. This is a classic continuation setup following a long accumulation. Post breakout, the price tested the upper region and is now preparing for a potential next leg toward Fibonacci extension levels. 🔑 Key Support & Resistance Levels: 🔵 Resistance / Upside Targets: ₹6,485.00 (Cup breakout top) ₹8,829.30 (Fib extension 161.8%) 🟦 🔴 Support Zones: ₹5,290.20 – Local horizontal support ₹5,035.95 – Fib 61.8% retracement (strong support) ₹4,588.30 – Fib 50% ₹4,140.70 – Fib 38.2% ₹2,691.65 – Long-term base (0% Fib) 🧭 Strategic View: 🟢 Bias: Bullish 🔁 Retest Zone: ₹5,290–₹5,035 can be re-entry zones 🎯 Target Zones: ₹6,485 followed by ₹8,829 for positional long 🛑 Invalidation: Below ₹5,000 zone ⚠️ Disclaimer: This is an educational chart setup and not trading advice. Please conduct your own research and risk management. 📣 Follow @PriceAction_Pulse for more such clean breakouts and chart pattern analysis! 🔁 Drop a comment if DIVISLAB is on your radar for the next breakout rally 📈
BSE:DIVISLABLong
by PriceAction_Pulse
DIVISLAB : Rounding Bottom Consolidation Breakout..!!DIVISLAB is showing good consolidation Breakout above the Rounding Bottom structure breakout.. target and sl are on the chart.... there is lot of scope in large cap stocks as the data shows.. All data is available in public domain.. CMP : 6580 TG : 7800 SL : 5840 Stock's selection based on 5 Point Analysis: 1: Idea : Breakout. 2: Support : Volume, Delivery . 3: Technical : 21/55/200-EMA, Super trend up, RS>0 RSI. 4: Fundamental : PE, PAT, Industry & peer PE and sector performance. 5: Timing : Entry Timing on Daily chart. Disclaimer : It is my personal view as a trader and for educational purpose only. Equity market involves risk . Please consult your financial adviser before taking any decision. Disclosure : might be Hold
NSE:DIVISLABLong
by SthitaprajnaYogi
1
#DIVISLAB - Stage 1 BreakOut / Keep in WL📊 Script: DIVISLAB Key highlights: 💡⚡ 📈 Stage 1 BreakOut in Daily Time Frame. 📈 Price consolidated near Resistance. 📈 BO with Volume 📈 MACD Crossover 📈 RS Line making 52WH 📈 Can go for a swing trade BUY ONLY ABOVE 6650 DCB ⏱️ C.M.P 📑💰- 6647 🟢 Target 🎯🏆 – 14% ⚠️ Stoploss ☠️🚫 – 7% ️⚠️ Important: Market conditions are Okish, Position size 50% per Trade. Protect Capital Always ⚠️ Important: Always Exit the trade before any Event. ⚠️ Important: Always maintain your Risk:Reward Ratio as 1:2, with this RR, you only need a 33% win rate to Breakeven. ✅Like and follow to never miss a new idea!✅ Disclaimer: I am not SEBI Registered Advisor. My posts are purely for training and educational purposes. Eat🍜 Sleep😴 TradingView📈 Repeat 🔁 Happy learning with MMT. Cheers!🥂
NSE:DIVISLABLong
by MMT_MakeMoneyTrading